Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jessica J. Lin"'
Autor:
David R. Gandara, Thomas E. Stinchcombe, Caroline E. McCoach, Alison M. Schram, Emilio Paul Araujo-Mino, Timmy Nguyen, Jorge Nieva, Aditya Bardia, Lesli A. Kiedrowski, Alessandro Russo, Janakiraman Subramanian, David S. Hong, Christian Rolfo, Kristin Price, Alexander Drilon, Afshin Dowlati, Jessica J. Lin, Stephen V. Liu, Michael A. Morse, Deepa Sashital, Mohammad Mobayed, Neelima Vidula, Shahrooz Eshaghian, Scott N. Gettinger, Sarah B. Goldberg
Publikováno v:
Br J Cancer
Background Activating fusions of the NTRK1, NTRK2 and NTRK3 genes are drivers of carcinogenesis and proliferation across a broad range of tumour types in both adult and paediatric patients. Recently, the FDA granted tumour-agnostic approvals of TRK i
Autor:
Islam Baiev, Jochen K. Lennerz, Lesli A. Kiedrowski, Mohammed Usman Syed, Chendi Li, Rebecca S. Heist, Samuel J. Klempner, Dejan Juric, Aaron N. Hata, Mustafa Sakhi, Katerina A. Fella, Ryan B. Corcoran, Alexa G. Michel, Justin F. Gainor, Junbing Zhang, Liron Bar-Peled, Jessica J. Lin, Meagan B. Ryan, Noritaka Tanaka, Giulia Siravegna
Publikováno v:
Cancer Discovery. 11:1913-1922
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Geoffrey R. Oxnard, Satoshi Yoda, Bruce G. Robinson, Eliana B. Gomez, Sarah-Jane Dawson, S. Michael Rothenberg, Justin F. Gainor, Dahlia Henry, Oliver Gautschi, Christine Khoo, Stephen Q. Wong, Edward Y. Zhu, Andrew T. Metcalf, Louis Stancato, Brian B. Tuch, Barbara J. Brandhuber, Steve Andrews, Jessica J. Lin, Lavinia Tan, Kevin Ronald Condroski, Vivek Subbiah, Lecia V. Sequist, Wayne Blosser, James F. Blake, Joshua Ballard, Kolakowski Gabrielle R, Kevin Ebata, Alexander Drilon, Benjamin Solomon, Michele Nguyen, Sebastian Hollizeck
Publikováno v:
Journal of Thoracic Oncology. 15:541-549
Introduction Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and R
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio
Autor:
Victor Vaz, John V. Heymach, Natalie I. Vokes, Liam F. Spurr, Jacklynn V. Egger, Biagio Ricciuti, Subba R. Digumarthy, Andrew D. Cherniack, Ferdinandos Skoulidis, Andrew J. Plodkowski, Michael Y. Tolstorukov, Xinan Wang, Jessica J. Lin, Nuno Vaz, Jianjun Zhang, Gonzalo Recondo, Deepti Venkatraman, Justin F. Gainor, David A. Barbie, Giuseppe Lamberti, Mehmet Altan, Yvonne Y. Li, Lingzhi Hong, Lynette M. Sholl, Hye Sun Park, Kathryn C. Arbour, Matthew D. Hellmann, Mark M. Awad, Mizuki Nishino, Amir Vajdi, Joao Victor Machado Alessi, Hira Rizvi, Sara Khosrowjerdi
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(3)
Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibiti
Autor:
Jessica J. Lin, Yunan Nie, Alexia Iasonos, Andrew J. Plodkowski, Maria E. Arcila, Debra A. Goldman, Jaime L. Schneider, Viola W. Zhu, Sai-Hong Ignatius Ou, Natasha Rekhtman, Alexander Drilon, Subba R. Digumarthy, Tejas Patil, Jamie E. Chaft, Christina Falcon, Andrew Do, Noura J. Choudhury, Soo-Ryum Yang
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187-(2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Autor:
Alice T. Shaw, Jochen K. Lennerz, Mari Mino-Kenudson, Hideko Isozaki, Subba R. Digumarthy, Inga T. Lennes, Rebecca J. Nagy, Corinne Clifford, Aaron N. Hata, Jessica J. Lin, Lecia V. Sequist, Mandeep Banwait, Amanda K. Riley, Dora Dias-Santagata, Justin F. Gainor, Zofia Piotrowska, Sai-Hong Ignatius Ou, Varuna Nangia, Viola W. Zhu, Rebecca S. Heist, Richard B. Lanman, Nicolas Marcoux, Wenjia Su, A. John Iafrate, Satoshi Yoda, Erica Evans, Beni B. Wolf
Publikováno v:
Cancer Discovery. 8:1529-1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired
Autor:
Jeeyun Lee, Byoung Chul Cho, Dayong Zhai, Wei Deng, David M. Hyman, Judy Nguyen, Myung-Ju Ahn, Juliet Liu, Dong Wan Kim, Viola W. Zhu, J. Jean Cui, Jeff Whitten, Alice T. Shaw, Shanna Stopatschinskaja, Robert C. Doebele, Zhongdong Huang, Sai-Hong Ignatius Ou, Jessica J. Lin, Evan Rogers, Alexander Drilon, D. Ross Camidge, John K.C. Lim
Publikováno v:
Cancer Discovery. 8:1227-1236
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1–3 rearrangements; however, resistance invariably devel
Autor:
Aaron C. Tan, Justin F. Gainor, Ibiayi Dagogo-Jack, Jennifer L Peterson, Daniel Shao-Weng Tan, Aaron N. Hata, Viola W. Zhu, Lori J. Wirth, Kylie Prutisto-Chang, Jessica J. Lin, Stephen V. Liu, Satoshi Yoda, Andrew Do, Lecia V. Sequist, Jochen K. Lennerz, Mari Mino-Kenudson, Caroline E. McCoach, Valentina Nardi, S-H.I. Ou
Publikováno v:
Ann Oncol
BACKGROUND: Rearranged during transfection (RET) gene fusions are a validated target in non-small cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::830014fd0f1de9ddd7f47bf0fd1d862b
https://europepmc.org/articles/PMC9538591/
https://europepmc.org/articles/PMC9538591/